Literature DB >> 1664857

Metabolism of hydralazine by activated leukocytes: implications for hydralazine induced lupus.

A H Hofstra1, L C Matassa, J P Uetrecht.   

Abstract

Hydralazine is associated with a lupus-like syndrome. There is evidence that many drug hypersensitivity reactions are due to reactive metabolites. Incubation of hydralazine with activated neutrophils or monocytes led to the production of phthalazinone, phthalazine and 3 unidentified metabolites. Formation of the metabolites, with the exception of phthalazine, required activation of the leukocytes. Using radiolabelled hydralazine, covalent binding to activated neutrophils was observed. Oxidation of hydralazine catalyzed by myeloperoxidase (MPO) produced the same metabolites and covalent binding to protein. We conclude that hydralazine is metabolized by activated leukocytes to a reactive metabolite which may be associated with hydralazine induced lupus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664857

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.

Authors:  J P Uetrecht
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 3.  Deleterious effects of reactive metabolites.

Authors:  Sabry M Attia
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

Review 4.  Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus.

Authors:  R L Rubin; A Kretz-Rommel
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

Review 5.  Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity.

Authors:  Dan A Erkes; Senthamil R Selvan
Journal:  J Immunol Res       Date:  2014-05-15       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.